NasdaqGS - Nasdaq Real Time Price • USD
Erasca, Inc. (ERAS)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:37 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 8 |
| Avg. Estimate | -0.2 | -0.21 | -0.9 | -0.96 |
| Low Estimate | -0.23 | -0.24 | -1.15 | -1.43 |
| High Estimate | -0.18 | -0.19 | -0.76 | -0.76 |
| Year Ago EPS | -0.22 | -0.21 | -0.83 | -0.9 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 7 | 6 |
| Avg. Estimate | -- | -- | -- | 950k |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | 5.72M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.31 | -0.24 | -0.22 | -0.23 |
| EPS Actual | -0.22 | -0.21 | -0.2 | -0.2 |
| Difference | 0.09 | 0.03 | 0.02 | 0.03 |
| Surprise % | 29.00% | 12.50% | 9.10% | 13.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.2 | -0.21 | -0.9 | -0.96 |
| 7 Days Ago | -0.2 | -0.21 | -0.9 | -0.96 |
| 30 Days Ago | -0.21 | -0.22 | -1.02 | -1.02 |
| 60 Days Ago | -0.22 | -0.22 | -1.04 | -0.95 |
| 90 Days Ago | -0.22 | -0.22 | -1.04 | -0.95 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 3 | 3 | 3 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ERAS | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 9.10% | -- | -- | 6.50% |
| Next Qtr. | 0.00% | -- | -- | 12.00% |
| Current Year | -8.40% | -- | -- | 5.30% |
| Next Year | -6.70% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -15.90% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Goldman Sachs: Buy to Buy | 4/2/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/28/2024 |
| Initiated | Capital One: Overweight | 3/11/2024 |
| Downgrade | B of A Securities: Buy to Neutral | 1/5/2024 |
| Maintains | Mizuho: Buy to Buy | 11/29/2023 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/28/2023 |
Related Tickers
ORIC ORIC Pharmaceuticals, Inc.
8.07
+5.22%
ZNTL Zentalis Pharmaceuticals, Inc.
11.06
+0.68%
BOLD Boundless Bio, Inc.
11.64
-3.56%
GLUE Monte Rosa Therapeutics, Inc.
5.33
-2.20%
FULC Fulcrum Therapeutics, Inc.
7.14
+0.14%
IPSC Century Therapeutics, Inc.
2.8800
-8.57%
YMAB Y-mAbs Therapeutics, Inc.
14.71
-0.88%
RVMD Revolution Medicines, Inc.
35.96
+1.78%
ENVB Enveric Biosciences, Inc.
0.8950
-2.45%
ELYM Eliem Therapeutics, Inc.
3.9800
+17.40%